Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc. (Nasdaq: ENSC) is a clinical-stage pharmaceutical company focused on developing abuse-deterrent opioid and stimulant medications using its proprietary TAAP and MPAR platform technologies. The company completed its transition to a public entity through a SPAC merger that closed in 2021, with the amended current report on Form 8-K/A filed on June 30, 2021 reflecting post-closing disclosures associated with that transaction. Operating in the biotechnology and specialty pharmaceutical sector, Ensysce targets the significant unmet need for safer controlled-substance formulations. The company trades on Nasdaq under the ticker ENSC. For complete filing history, transaction documents, and ongoing SPAC data on Ensysce and hundreds of other deals, sign up for full access at SpacDesk.